These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 9829398)

  • 1. Protection of pregnant cattle and their fetuses against infection with bovine viral diarrhea virus type 1 by use of a modified-live virus vaccine.
    Cortese VS; Grooms DL; Ellis J; Bolin SR; Ridpath JF; Brock KV
    Am J Vet Res; 1998 Nov; 59(11):1409-13. PubMed ID: 9829398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of modified-live bovine viral diarrhea virus vaccines containing either type 1 or types 1 and 2 BVDV on heifers and their offspring after challenge with noncytopathic type 2 BVDV during gestation.
    Ficken MD; Ellsworth MA; Tucker CM; Cortese VS
    J Am Vet Med Assoc; 2006 May; 228(10):1559-64. PubMed ID: 16677126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fetal protection following exposure to calves persistently infected with bovine viral diarrhea virus type 2 sixteen months after primary vaccination of the dams.
    Ellsworth MA; Fairbanks KK; Behan S; Jackson JA; Goodyear M; Oien NL; Meinert TR; Leyh RD
    Vet Ther; 2006; 7(3):295-304. PubMed ID: 17039452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fetal protection against continual exposure to bovine viral diarrhea virus following administration of a vaccine containing an inactivated bovine viral diarrhea virus fraction to cattle.
    Grooms DL; Bolin SR; Coe PH; Borges RJ; Coutu CE
    Am J Vet Res; 2007 Dec; 68(12):1417-22. PubMed ID: 18052749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three commercial vaccines for preventing persistent infection with bovine viral diarrhea virus.
    Rodning SP; Marley MS; Zhang Y; Eason AB; Nunley CL; Walz PH; Riddell KP; Galik PK; Brodersen BW; Givens MD
    Theriogenology; 2010 May; 73(8):1154-63. PubMed ID: 20181385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy of a modified-live combination vaccine against bovine viral diarrhea virus types 1 and 2 challenge exposures in a one-year duration-of-immunity fetal protection study.
    Ficken MD; Ellsworth MA; Tucker CM
    Vet Ther; 2006; 7(3):283-94. PubMed ID: 17039451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine viral diarrhea virus fetal persistent infection after immunization with a contaminated modified-live virus vaccine.
    Palomares RA; Marley SM; Givens MD; Gallardo RA; Brock KV
    Theriogenology; 2013 May; 79(8):1184-95. PubMed ID: 23561853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental fetal challenge using type II bovine viral diarrhea virus in cattle vaccinated with modified-live virus vaccine.
    Brock KV; Cortese VS
    Vet Ther; 2001; 2(4):354-60. PubMed ID: 19746658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects against abortion and fetal infection following exposure to bovine viral diarrhea virus and bovine herpesvirus 1 during pregnancy in beef heifers that received two doses of a multivalent modified-live virus vaccine prior to breeding.
    Givens MD; Marley MS; Jones CA; Ensley DT; Galik PK; Zhang Y; Riddell KP; Joiner KS; Brodersen BW; Rodning SP
    J Am Vet Med Assoc; 2012 Aug; 241(4):484-95. PubMed ID: 22852575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection.
    Kovács F; Magyar T; Rinehart C; Elbers K; Schlesinger K; Ohnesorge WC
    Vet Microbiol; 2003 Oct; 96(2):117-31. PubMed ID: 14519330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection from persistent infection with a bovine viral diarrhea virus (BVDV) type 1b strain by a modified-live vaccine containing BVDV types 1a and 2, infectious bovine rhinotracheitis virus, parainfluenza 3 virus and bovine respiratory syncytial virus.
    Xue W; Mattick D; Smith L
    Vaccine; 2011 Jun; 29(29-30):4657-62. PubMed ID: 21596076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fetal protection in heifers vaccinated with a modified-live virus vaccine containing bovine viral diarrhea virus subtypes 1a and 2a and exposed during gestation to cattle persistently infected with bovine viral diarrhea virus subtype 1b.
    Leyh RD; Fulton RW; Stegner JE; Goodyear MD; Witte SB; Taylor LP; Johnson BJ; Step DL; Ridpath JF; Holland BP
    Am J Vet Res; 2011 Mar; 72(3):367-75. PubMed ID: 21355740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of protection against systemic infection and disease from experimental bovine viral diarrhea virus type 2 infection by use of a modified-live noncytopathic type 1 vaccine in calves.
    Kelling CL; Hunsaker BD; Steffen DJ; Topliff CL; Eskridge KM
    Am J Vet Res; 2007 Jul; 68(7):788-96. PubMed ID: 17605616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine.
    Fairbanks KK; Rinehart CL; Ohnesorge WC; Loughin MM; Chase CC
    J Am Vet Med Assoc; 2004 Dec; 225(12):1898-904. PubMed ID: 15643841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against fetal infection with either bovine viral diarrhea virus type 1 or type 2 using a noncytopathic type 1 modified-live virus vaccine.
    Brock KV; McCarty K; Chase CC; Harland R
    Vet Ther; 2006; 7(1):27-34. PubMed ID: 16598681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of persistent infection in calves by vaccination of dams with noncytopathic type-1 modified-live bovine viral diarrhea virus prior to breeding.
    Dean HJ; Hunsaker BD; Bailey OD; Wasmoen T
    Am J Vet Res; 2003 May; 64(5):530-7. PubMed ID: 12755290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fetal protection against bovine viral diarrhoea type 1 virus infection after one administration of a live-attenuated vaccine.
    Meyer G; Deplanche M; Roux D; Moulignie M; Picard-Hagen N; Lyazrhi F; Raboisson D; Mathevet P; Schelcher F
    Vet J; 2012 May; 192(2):242-5. PubMed ID: 21689959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity and duration of neutralizing antibodies induced in healthy cattle after administration of a modified-live virus vaccine against bovine viral diarrhea.
    Cortese VS; Whittaker R; Ellis J; Ridpath JF; Bolin SR
    Am J Vet Res; 1998 Jul; 59(7):848-50. PubMed ID: 9659549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of reproductive protection against bovine viral diarrhea virus and bovine herpesvirus-1 afforded by annual revaccination with modified-live viral or combination modified-live/killed viral vaccines after primary vaccination with modified-live viral vaccine.
    Walz PH; Givens MD; Rodning SP; Riddell KP; Brodersen BW; Scruggs D; Short T; Grotelueschen D
    Vaccine; 2017 Feb; 35(7):1046-1054. PubMed ID: 28111144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a modified live virus type-1a bovine viral diarrhea virus vaccine (Singer strain) against a type-2 (strain 890) challenge.
    Fairbanks K; Schnackel J; Chase CC
    Vet Ther; 2003; 4(1):24-34. PubMed ID: 12756633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.